Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9844510 | LAB HRA PHARMA | Ulipristal acetate tablets |
Dec, 2028
(5 years from now) | |
US8735380 | LAB HRA PHARMA | Ulipristal acetate tablets |
Feb, 2029
(5 years from now) | |
US10159681 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(6 years from now) | |
US10772897 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(6 years from now) | |
US9283233 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(6 years from now) | |
US8512745 | LAB HRA PHARMA | Ulipristal acetate tablets |
Jun, 2030
(6 years from now) | |
US8426392 | LAB HRA PHARMA | Method for providing emergency contraception |
Jun, 2030
(6 years from now) | |
US8962603 | LAB HRA PHARMA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(6 years from now) |
Ella is owned by Lab Hra Pharma.
Ella contains Ulipristal Acetate.
Ella has a total of 8 drug patents out of which 0 drug patents have expired.
Ella was authorised for market use on 13 August, 2010.
Ella is available in tablet;oral dosage forms.
Ella can be used as a method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse, ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food, method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99, method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse, a method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse.
The generics of Ella are possible to be released after 12 June, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
Market Authorisation Date: 13 August, 2010
Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; ...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic